Total Payments
$29,551
2024 Payments
$23,567
Companies
8
Transactions
21
Medicare Patients
845
Medicare Billing
$119,869
Payment Breakdown by Category
Consulting$15,992 (54.1%)
Other$11,189 (37.9%)
Research$2,260 (7.6%)
Education$110.61 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,992 | 10 | 54.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,189 | 3 | 37.9% |
| Unspecified | $2,260 | 1 | 7.6% |
| Education | $110.61 | 7 | 0.4% |
Payments by Type
General
$27,291
20 transactions
Research
$2,260
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $18,221 | 7 | $0 (2024) |
| GENZYME CORPORATION | $8,106 | 2 | $0 (2024) |
| PTC Therapeutics, Inc. | $2,000 | 1 | $0 (2021) |
| Vertex Pharmaceuticals Incorporated | $525.00 | 2 | $0 (2021) |
| Dr.Reddy's Laboratories,Inc. | $356.00 | 1 | $0 (2018) |
| Purdue Pharma L.P. | $233.00 | 1 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $99.46 | 1 | $0 (2023) |
| Travere Therapeutics, Inc. | $11.15 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,567 | 7 | Biogen, Inc. ($15,461) |
| 2023 | $600.29 | 3 | Biogen, Inc. ($500.00) |
| 2022 | $9.49 | 4 | Travere Therapeutics, Inc. ($9.49) |
| 2021 | $4,785 | 4 | Biogen, Inc. ($2,260) |
| 2020 | $0.83 | 1 | Travere Therapeutics, Inc. ($0.83) |
| 2018 | $589.00 | 2 | Dr.Reddy's Laboratories,Inc. ($356.00) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,562.00 | General |
| 07/02/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,544.00 | General |
| 06/07/2024 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,082.50 | General |
| 05/30/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Consulting Fee | Cash or cash equivalent | $2,343.00 | General |
| Category: Neurology | ||||||
| 03/21/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| Category: Neurology | ||||||
| 03/07/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Neurology | ||||||
| 03/01/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| 10/27/2023 | Teva Pharmaceuticals USA, Inc. | — | Education | In-kind items and services | $99.46 | General |
| 10/06/2023 | Biogen, Inc. | Skyclarys (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Neurology | ||||||
| 07/18/2023 | Travere Therapeutics, Inc. | Cholbam (Drug) | Education | In-kind items and services | $0.83 | General |
| Category: Hepatology | ||||||
| 10/18/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Education | In-kind items and services | $6.87 | General |
| Category: Hepatology | ||||||
| 10/18/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Education | In-kind items and services | $0.96 | General |
| Category: Hepatology | ||||||
| 10/18/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Education | In-kind items and services | $0.83 | General |
| Category: Hepatology | ||||||
| 10/18/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Education | In-kind items and services | $0.83 | General |
| Category: Hepatology | ||||||
| 11/04/2021 | Biogen, Inc. | — | — | Cash or cash equivalent | $2,260.00 | Research |
| Study: A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3 | ||||||
| 10/29/2021 | PTC Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 05/24/2021 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $180.83 | General |
| 04/29/2021 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $344.17 | General |
| 01/07/2020 | Travere Therapeutics, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $0.83 | General |
| Category: Hepatology | ||||||
| 05/22/2018 | Dr.Reddy's Laboratories,Inc. | — | Consulting Fee | Cash or cash equivalent | $356.00 | General |
| 04/28/2018 | Purdue Pharma L.P. | — | Consulting Fee | Cash or cash equivalent | $233.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3 | Biogen, Inc. | $2,260 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 184 | 237 | $189,180 | $23,905 |
| 2022 | 4 | 205 | 293 | $243,850 | $32,882 |
| 2021 | 6 | 228 | 314 | $263,243 | $35,854 |
| 2020 | 6 | 228 | 304 | $149,138 | $27,228 |
Total Patients
845
Total Services
1,148
Medicare Billing
$119,869
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 108 | $92,664 | $10,652 | 11.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 60 | 74 | $71,040 | $9,902 | 13.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 39 | $19,812 | $2,725 | 13.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 16 | $5,664 | $626.54 | 11.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 95 | 158 | $151,680 | $22,458 | 14.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 74 | $63,492 | $6,878 | 10.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 46 | $23,368 | $2,992 | 12.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 15 | $5,310 | $553.69 | 10.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 74 | 121 | $116,160 | $17,384 | 15.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 80 | 102 | $87,516 | $9,973 | 11.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 35 | 44 | $22,352 | $3,061 | 13.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $21,760 | $2,984 | 13.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 12 | 20 | $3,520 | $1,258 | 35.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $11,935 | $1,194 | 10.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 87 | 128 | $81,920 | $13,390 | 16.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 69 | 89 | $50,730 | $8,474 | 16.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 18 | 26 | $4,004 | $2,273 | 56.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 22 | 24 | $9,744 | $1,404 | 14.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 21 | 26 | $2,080 | $1,330 | 63.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 11 | 11 | $660.00 | $358.11 | 54.3% |
About Dr. Susan Perlman, MD
Dr. Susan Perlman, MD is a Neurodevelopmental Disabilities healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114945474.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Susan Perlman, MD has received a total of $29,551 in payments from pharmaceutical and medical device companies, with $23,567 received in 2024. These payments were reported across 21 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($15,992).
As a Medicare-enrolled provider, Perlman has provided services to 845 Medicare beneficiaries, totaling 1,148 services with total Medicare billing of $119,869. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurodevelopmental Disabilities
- Other Specialties Neurology
- Location Los Angeles, CA
- Active Since 07/17/2006
- Last Updated 01/21/2020
- Taxonomy Code 2084P0005X
- Entity Type Individual
- NPI Number 1114945474
Products in Payments
- SKYCLARYS (Drug) $8,953
- Skyclarys (Drug) $500.00
- Cholbam (Drug) $10.32
- (820) Cholbam (Drug) $0.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurodevelopmental Disabilities Doctors in Los Angeles
Dr. William Shields, M.d, M.D
Neurodevelopmental Disabilities — Payments: $9.7M
Neurodevelopmental Disabilities $9.7M
Raman Sankar, M.d, M.D
Neurodevelopmental Disabilities — Payments: $1.1M
Neurodevelopmental Disabilities $1.1M
Joyce Wu, M.d, M.D
Neurodevelopmental Disabilities — Payments: $42,273
Neurodevelopmental Disabilities $42,273
Dr. Jason Lerner, M.d, M.D
Neurodevelopmental Disabilities — Payments: $12,156
Neurodevelopmental Disabilities $12,156
Daniel Geschwind, Md, MD
Neurodevelopmental Disabilities — Payments: $10,472
Neurodevelopmental Disabilities $10,472
Dr. Christopher Giza, M.d, M.D
Neurodevelopmental Disabilities — Payments: $6,790
Neurodevelopmental Disabilities $6,790